First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...

Lirilumab clinical development ongoing, including Phase II monotherapy trial in AML and three Phase I combination trials with nivolumab and elotuzumab Clinical program for lirilumab broadened with two...

Two posters presented by Bristol-Myers Squibb and Innate Pharma Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces...

Cash, cash equivalent and financial instruments amounting to 74.7 million euros Cash horizon to end of 2017 unchanged Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate...

IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015 IPH4102 shows potent...

“Site-specific conjugation by BTG improves the therapeutic index of ADC in vivo ” “Versatility of Site-Specific Conjugation based on Bacterial Transglutaminase” Innate Pharma SA (the “Company” -...

This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma This new Phase I initiated by Bristol...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

Acquisition in February 2014 of IPH2201, anti-NKG2A antibody, a Phase II-ready first-in-class checkpoint inhibitor Successful €50m capital increase subscribed by specialized investors Cash and cash...